

Received 9 September 2024 Accepted 11 September 2024

Edited by X. Hao, Institute of Chemistry, Chinese Academy of Sciences

‡ Additional correspondence author, e-mail: achyuta11@gmail.com.

**Keywords:** crystal [structure;](https://scripts.iucr.org/cgi-bin/full_search?words=crystal%20structure&Action=Search) [synthesis;](https://scripts.iucr.org/cgi-bin/full_search?words=synthesis&Action=Search) [benzenesulfonamide;](https://scripts.iucr.org/cgi-bin/full_search?words=benzene­sulfonamide&Action=Search) [hydrogen](https://scripts.iucr.org/cgi-bin/full_search?words=hydrogen%20bonding&Action=Search) bonding; [Hirshfeld](https://scripts.iucr.org/cgi-bin/full_search?words=Hirshfeld%20surface%20analysis&Action=Search) surface analysis; [docking;](https://scripts.iucr.org/cgi-bin/full_search?words=docking&Action=Search) [EGFR](https://scripts.iucr.org/cgi-bin/full_search?words=EGFR%20kinase&Action=Search) [kinase.](https://scripts.iucr.org/cgi-bin/full_search?words=EGFR%20kinase&Action=Search)

**CCDC reference:** [2364967](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=csd&csdid=2364967)

**Supporting information:** this article has supporting information at journals.iucr.org/e



# **Crystal structure and Hirshfeld surface analysis of (***E***)-***N***-(2-styrylphenyl)benzenesulfonamide**

**Dharani Albert A. M.,<sup>a</sup> Achyuta Nagaraj,<sup>a</sup> ‡ Kanagasabai Somarathinam,<sup>a</sup> Pavunkumar Vinayagam,<sup>b</sup> Mohanakrishnan Arasambattu K.<sup>b</sup> and Gugan Kothandan<sup>a</sup> \***

**a** CAS in Crystallography and Biophysics, University of Madras, Chennai, India, and **<sup>b</sup>** Department of Organic Chemistry, University of Madras, Chennai, India. \*Correspondence e-mail: [drgugank@gmail.com](mailto:drgugank@gmail.com)

The crystal structure of the title compound  $C_{20}H_{17}NO_2S$  features hydrogenbonding and  $C-H \cdot \cdot \pi$  interactions. Hirshfeld surface analysis revealed that  $H \cdots H$ ,  $C \cdots H/H \cdots C$  and  $O \cdots H/H \cdots O$  interactions make a major contribution to the crystal packing. Docking studies were carried out to determine the binding affinity and interaction profile of the title compound with EGFR kinase, a member of the ErbB family of receptor tyrosine kinases, which is crucial for processes such as cell proliferation and differentiation. The title compound shows a strong binding affinity with EGFR kinase, with the most favourable conformation having a binding energy of  $-8.27$  kcal mol<sup>-1</sup> and a predicted IC50 of 870.34 n*M*, indicating its potential as a promising candidate for targeted lung cancer therapy.

### **1. Chemical context**

The indole structure is widely regarded as a privileged scaffold, capable of serving as a ligand for various biological targets (Kaushik *et al.*, 2013). Indoles are prevalent across a broad spectrum of natural sources, including plants, animals and microorganisms. Numerous indole-containing compounds exhibit notable biological activities; for instance, indole-based alkaloids such as serotonin, tryptamine, and ergotamine are crucial in regulating physiological processes and significantly impact human health and behaviour. Indoles are also present in a variety of pharmaceuticals, such as antipsychotic, antidepressant and antimicrobial drugs. Beyond their biological significance, indoles are valuable as they are versatile building blocks in organic synthesis, with the indole ring being functionalized and modified to produce a diverse array of chemical compounds. Although many methods for synthesizing indole derivatives exist, there remains a strong interest in developing new and more efficient synthesis techniques. The transformation of 2-alkenylanilines into indoles has gained popularity as a straightforward approach due to the widespread availability of both anilines and alkenes (or styrenes). One such method involves C—H amination *via* transition-metal catalysts. Recently, methods that avoid the use of metals in cyclization have garnered considerable attention (Hegedus *et al.*, 1978; Larock *et al.*, 1996; Maity *et al.*, 2012; Youn *et al.*, 2015, 2016). A reaction was carried out with the aim of synthesizing 2-phenylindole from (*E*)-*N*-(2-styrylphenyl)benzenesulfonamide through PIDA/BF<sub>3</sub>·OEt<sub>2</sub>-mediated intramolecular cyclization and the structure of the (*E*)-*N*-(2-styrylphenyl) benzenesulfonamide intermediate of 2-phenylindole was confirmed through X-ray diffraction analysis.



#### **2. Structural commentary**

In the title compound, the sulfur atom is bound to two oxygens, a nitrogen (which is connected to another aromatic ring) and a carbon atom, forming a tetrahedral structure between the two aromatic moieties with sulfur at the centre. Relevant bond lengths and angles are given in Table 1. For the C1–C6 ring, the weighted average bond distance is 1.3959  $\AA$ , the weighted average absolute torsion angle is  $0.34^\circ$  and the pseudo-rotation parameter  $(\tau)$  is 0.3°. The C7–C12 ring has a weighted average bond distance of  $1.3899 \text{ Å}$ , a weighted average absolute torsion angle of  $0.83^\circ$  and a  $\tau$  value of 0.8. Similarly, the C15–C20 ring exhibits a weighted average bond distance of 1.3925  $\AA$ , a weighted average absolute torsion angle of  $1.76^\circ$  and  $\tau$  value of 1.8°. An intramolecular  $C7 - H7 \cdots O2$  hydrogen bond (Fig. 1, Table 2) directs the relative orientation of the C7–C12 ring in the molecular structure.

#### **3. Supramolecular features**

In the crystal,  $N1-H1\cdots O1$  and  $C6-H6\cdots O2$  hydrogen bonds and  $C-H \cdot \cdot \pi$  interactions (Table 1) are observed. The packing is shown in Fig. 2.

#### **4. Database survey**

A search in the Cambridge Structural Database (CSD, Version 5.45; Groom *et al.*, 2016) for the term '(styrylphenyl)-



#### **Figure 1**

View of title compound showing the atom-numbering scheme with displacement ellipsoids drawn at the 50% probability level. The intramolecular  $C7 - H7 \cdots O2$  hydrogen bond is shown as a dashed line.





#### **Table 2**

Hydrogen-bond geometry  $(\AA, \degree)$ .

*Cg*1 is the centroid of the C1–C6 ring.



Symmetry codes: (i)  $-x+1$ ,  $-y+1$ ,  $-z+1$ ; (ii)  $-x+1$ ,  $y-\frac{1}{2}$ ,  $-z+\frac{3}{2}$ ; (iii)  $x, y+1, z$ ;  $(iv) x, -y + \frac{3}{2}, z - \frac{1}{2}.$ 

benzenesulfonamide' gave one hit, (*Z*)-*N*-(difluoromethyl)-4 methyl-*N*-(2-styrylphenyl)benzenesulfonamide (CSD refcode HINBEO; Polley *et al.*, 2018). In this structure there is a difluromethyl group attached to the nitrogen in addition to a



**Figure 2** The crystal packing of the title compound viewed along the *a* axis.



**Figure 3** The Hirshfeld surface of the title compound mapped over  $d_{\text{norm}}$ .

methyl group at the *para* position of the benzene ring of benzenesulfonamide.

### **5. Hirshfeld surface analysis**

The Hirshfeld surface analysis was carried out using *Crystal Explorer 21* (Spackman *et al.*, 2021) to study the non-covalent interactions and the interatomic contacts. The Hirshfeld surface mapped over  $d_{\text{norm}}$  with shorter contacts in red, contacts around the van der Waals separation in white and longer contacts in blue is shown in Fig. 3.

The two-dimensional fingerprint plots for significant contacts are given in Fig. 4. The contacts making the largest contributions are  $H \cdot \cdot H$  (40.1%) due to the large number of hydrogen atoms in the molecule,  $C \cdot \cdot H/H \cdot \cdot \cdot C$  (37.1%) and  $O \cdot \cdot H/H \cdot \cdot \cdot O$  (19.7%). Contacts making minor contributions include  $C \cdots C$  (1.4%),  $N \cdots H/H \cdots N$  (1.3%) and  $O \cdots C/C \cdots O$  $(0.4\%)$ .

#### **6.** *In silico* **analysis**

Molecular docking studies were carried out to assess the potential of the title compound as a therapeutic agent by targeting EGFR kinase, a key protein involved in lung cancer development (Kavarthapu *et al.*, 2021). Dysregulation of EGFR, often through mutations or overexpression, is a major driver of non-small cell lung cancer (NSCLC), making it a key therapeutic target.

Docking was carried out using *AutoDock 4.2* (Morris *et al.*, 2009) software, with the EGFR kinase's high-resolution 3D crystal structure (PDB ID: 2ITY; Yun *et al.*, 2007) obtained from the Protein Data Bank (Berman *et al.*, 2000). Prior to docking, co-crystallized ligands and solvent molecules were removed using *PyMOL* (DeLano, 2002), the polar hydrogen atoms were added and the Kollman and Gasteiger charges were assigned to the protein. *AutoGrid* was used to calculate grid parameters, with a  $40 \times 40 \times 40$  point grid box and a spacing of 0.375  $\AA$ , centered on the binding site determined by the ligand-bound EGFR kinase (2ITY). Docking was conducted with the Lamarckian Genetic Algorithm (LGA) for 100 independent runs, keeping all other parameters at default. The protein was treated as rigid, while the ligand was allowed full flexibility. Docking results were evaluated based on binding interactions, binding energy (kcal  $mol^{-1}$ ), and predicted inhibitory concentration (IC50). The docking results showed that  $(E)$ -*N*-(2-styrylphenyl)benzenesulfonamide has a strong binding affinity for EGFR kinase, with the most favourable conformation having a binding energy of  $-8.27$ kcal mol<sup> $-1$ </sup> and a predicted IC50 of 870.34 n*M*.

Further interaction analysis shows that the ligand forms a hydrogen bond with the MET-793 residue at 3.0  $\AA$ , a crucial interaction for the stability of the ligand–protein complex (Fig. 5). Additionally, the compound engages in various noncovalent interactions, including  $\pi$ –alkyl with VAL-726, ALA-743, LYS-745, LEU-788, and LEU-792;  $\pi$ -sigma with LEU-718, THR-790, and LEU-844; pi-sulfur with CYS-797; and van der Waals with ILE-744, MET-766, PRO-794, GLY-796, and



#### **Figure 4**

The various two dimensional fingerprint plots with the significant contacts labelled.

## **research communications**



**Figure 5**

Molecular docking results illustrating the interaction of the title compound with EGFR kinase. (*a*) Hydrogen-bond interaction and (*b*) overall interactions (the vdW,  $\pi$ –alkyl,  $\pi$ –sigma, and  $\pi$ –sulfur interactions are indicated in green, pink, purple, and yellow, respectively)

THR-854. These interactions collectively enhance the ligand's stability and affinity for EGFR kinase.

Considering EGFR's critical role in NSCLC, the interaction profile suggests the potential of the title compound as a therapeutic agent. Its strong binding affinity and specific interactions with EGFR kinase highlight its promise for further development in targeted lung cancer treatment, particularly for patients with EGFR mutations.

#### **7. Synthesis and crystallization**

To a hot solution of (*E*)-1-nitro-2-styrylbenzene (2.9 g, 12.88 mmol) in 50 mL of an EtOH–AcOH mixture (4:1 ratio), Fe powder (3.5 g, 64.40 mmol) was added, and the reaction mixture was refluxed for 6 h. Once the reaction was complete, as monitored by TLC, the solution was carefully decanted to remove the iron residue and then poured over crushed ice (100 g) containing 5 mL of concentrated HCl. The resulting solid was filtered and dried over CaCl<sub>2</sub>. The crude product was used directly in the next step without further purification. Subsequently, a solution of the resulting amine salts (2.2 g, 9.52 mmol) in dry DCM (20 mL) was prepared, to which benzenesulfonyl chloride (1.3 mL, 10.47 mmol) and pyridine (0.92 mL, 11.42 mmol) were slowly added. The mixture was stirred at room temperature for 8 h under a nitrogen atmo-





Computer programs: *CrysAlis PRO* (Rigaku OD, 2022), *SHELXT2018/2* (Sheldrick, 2015*a*), *SHELXL2019/3* (Sheldrick, 2015*b*) and *OLEX2* (Dolomanov *et al.*, 2009).

sphere. After the reaction was complete, as monitored by TLC, the mixture was poured into ice–water (50 mL) containing 1 mL of concentrated HCl, extracted with DCM  $(2 \times 20 \text{ mL})$ , and then washed with water  $(2 \times 20 \text{ mL})$  and dried over  $Na<sub>2</sub>SO<sub>4</sub>$ . The solvent was removed under reduced pressure, and the crude product was triturated with diethyl ether (10 mL), yielding (*E*)-*N*-(2-styrylphenyl)benzenesulfonamide (2.3 g, 61% yield over two steps) as a white solid, m.p. 399–401 K.

#### **8. Refinement**

Crystal data, data collection and structure refinement details are summarized in Table 3. The N-bound H atom was fully refined. C-bound H atoms were positioned geometrically  $(C-H = 0.95 \text{ Å})$  with  $U_{\text{iso}}(H) = 1.2 U_{\text{eq}}(C)$ .

#### **References**

- Berman, H. M., [Westbrook,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB1) J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., [Shindyalov,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB1) I. N. & Bourne, P. E. (2000). *Nucleic Acids Res.* **28**, [235–242.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB1)
- DeLano, W. L. (2002). *CCP4 Newsl. Protein [Crystallogr](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB2)*. **40**, 82–92.
- [Dolomanov,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB3) O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & [Puschmann,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB3) H. (2009). *J. Appl. Cryst.* **42**, 339–341.
- Groom, C. R., Bruno, I. J., [Lightfoot,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB4) M. P. & Ward, S. C. (2016). *Acta Cryst.* B**72**, [171–179.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB4)
- Hegedus, L. S., Allen, G. F., Bozell, J. J. & [Waterman,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB5) E. L. (1978). *J. Am. Chem. Soc.* **100**, [5800–5807.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB5)

# **research communications**

- Kaushik, N. K., [Kaushik,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB6) N., Attri, P., Kumar, N., Kim, C. H., Verma, A. K. & Choi, E. H. (2013). *Molecules*, **18**, [6620–6662.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB6)
- Kavarthapu, R., [Anbazhagan,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB7) R. & Dufau, M. L. (2021). *Cancers*, **13**, [4685.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB7)
- Larock, R. C., [Hightower,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB8) T. R., Hasvold, L. A. & Peterson, K. P. (1996). *J. Org. Chem.* **61**, [3584–3585.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB8)
- Maity, S. & Zheng, N. A. (2012). *[Angew.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB9) Chem. Int. Ed.* **51**, 9562– [9566.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB9)
- Morris, G. M., Huey, R., [Lindstrom,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB10) W., Sanner, M. F., Belew, R. K., [Goodsell,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB10) D. S. & Olson, A. J. (2009). *J. Comput. Chem.* **30**, 2785– [2791.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB10)
- Polley, A., Bairy, G., Das, P. & Jana, R. [\(2018\).](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB18) *Adv Synth Catal.* **360**, [4161–4167.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB18)
- Rigaku OD (2022). *CrysAlis PRO*. Rigaku Oxford [Diffraction,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB19) Yarnton, [England.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB19)
- [Sheldrick,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB11) G. M. (2015*a*). *Acta Cryst.* A**71**, 3–8.
- [Sheldrick,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB12) G. M. (2015*b*). *Acta Cryst.* C**71**, 3–8.
- Spackman, P. R., Turner, M. J., [McKinnon,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB13) J. J., Wolff, S. K., Grimwood, D. J., Jayatilaka, D. & [Spackman,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB13) M. A. (2021). *J. Appl. Cryst.* **54**, [1006–1011.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB13)
- Youn, S. W., Jang, S. S. & Lee, S. R. (2016). *[Tetrahedron](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB14)*, **72**, 4902– [4909.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB14)
- Youn, S. W., Ko, T. Y., Jang, M. J. & Jang, S. S. [\(2015\).](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB15) *Adv. Synth. Catal.* **357**, [227–234.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB15)
- Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., [Meyerson,](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB16) M. & Eck, M. J. (2007). *Cancer Cell*, **11**, [217–227.](https://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdfbb&cnor=nx2013&bbid=BB16)

# **supporting information**

*Acta Cryst.* (2024). E**80**, 1034-1038 [https://doi.org/10.1107/S2056989024008892]

**Crystal structure and Hirshfeld surface analysis of (***E***)-***N***-(2-styrylphenyl) benzenesulfonamide**

# **Dharani Albert A. M., Achyuta Nagaraj, Kanagasabai Somarathinam, Pavunkumar Vinayagam, Mohanakrishnan Arasambattu K. and Gugan Kothandan**

**Computing details** 

*N***-{2-[(***E***)-2-Phenylethenyl]phenyl}benzenesulfonamide** 

### *Crystal data*

 $C_{20}H_{17}NO_2S$  $M_r = 335.40$ Monoclinic, *P*21/*c*  $a = 13.7320(1)$  Å  $b = 8.2475(1)$  Å  $c = 15.5387(2)$  Å  $\beta$  = 107.505 (1)<sup>o</sup>  $V = 1678.33(3)$  Å<sup>3</sup>  $Z = 4$ 

## *Data collection*

SuperNova, Dual, Cu at home/near, HyPix diffractometer Radiation source: micro-focus sealed X-ray tube, SuperNova (Cu) X-ray Source Mirror monochromator Detector resolution: 10.0000 pixels mm-1 *ω* scans Absorption correction: gaussian (CrysAlisPro; Rigaku OD, 2022)

## *Refinement*

Refinement on *F*<sup>2</sup> Least-squares matrix: full  $R[F^2 > 2\sigma(F^2)] = 0.032$  $wR(F^2) = 0.084$  $S = 1.07$ 3562 reflections 221 parameters 0 restraints Primary atom site location: dual  $F(000) = 704$  $D_x = 1.327$  Mg m<sup>-3</sup> Cu *Ka* radiation,  $\lambda = 1.54184 \text{ Å}$ Cell parameters from 18551 reflections  $\theta$  = 5.1–77.6°  $\mu = 1.80$  mm<sup>-1</sup>  $T = 100 \text{ K}$ Block, clear intense colourless  $0.21 \times 0.14 \times 0.1$  mm

 $T_{\text{min}} = 0.560, T_{\text{max}} = 1.000$ 37664 measured reflections 3562 independent reflections 3380 reflections with  $I > 2\sigma(I)$  $R_{\text{int}} = 0.039$  $\theta_{\text{max}} = 77.7^{\circ}, \theta_{\text{min}} = 3.4^{\circ}$  $h = -17 \rightarrow 17$  $k = -10 \rightarrow 10$ *l* = −19→19

Hydrogen site location: mixed H atoms treated by a mixture of independent and constrained refinement  $w = 1/[\sigma^2 (F_o^2) + (0.0413P)^2 + 0.655P]$ where  $P = (F_o^2 + 2F_c^2)/3$  $(\Delta/\sigma)_{\text{max}} = 0.001$ Δ*ρ*max = 0.36 e Å−3  $\Delta\rho_{\rm min} = -0.46$  e Å<sup>-3</sup>

## *Special details*

**Geometry**. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.



*Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å<sup>2</sup>)* 

# **supporting information**

H12	0.255793	1.091263	0.561936	$0.040*$
H1	0.4039(13)	0.447(2)	0.5188(12)	$0.036(4)$ *

*Atomic displacement parameters (Å2 )*



*Geometric parameters (Å, º)*



# **supporting information**





*Hydrogen-bond geometry (Å, º)*

*Cg*1 is the centroid of the C1–C6 ring.



Symmetry codes: (i) −*x*+1, −*y*+1, −*z*+1; (ii) −*x*+1, *y*−1/2, −*z*+3/2; (iii) *x*, *y*+1, *z*; (iv) *x*, −*y*+3/2, *z*−1/2.